


**AMENDMENTS TO THE CLAIMS:**

*This listing of the claims below will replace all prior versions and listing of claims in this application.*


1. (Currently Amended) ~~Use of guanidine derivatives~~ A method of antagonizing a neuropeptide FF receptor comprising administering to a patient an effective amount a guanidine derivative of general formula



in which A represents a chain of 3-6 optionally substituted C atoms, one of which can be replaced by -N(R')- or -O-; and R' represents hydrogen or a substitute; the ring skeleton containing only the two double bonds of the thiazole component; of pharmaceutically applicable acid addition salts of basic compounds of formula I, pharmaceutically applicable salts of acid group-containing compounds of formula I with bases, pharmaceutically applicable esters of hydroxy or carboxy group-containing compounds of formula I and hydrates or solvates thereof; as neuropeptide FF receptor antagonists or for the preparation of corresponding medicinal products.

2. (Currently Amended) ~~Use~~ The method according to claim 1 ~~wherein said antagonizing of said neuropeptide FF receptor agonists is for the treatment of pain and hyperalgesia, withdrawal syndromes in the case of alcohol, psychotropic and nicotine dependences~~ dependencies and for the improvement or elimination of these ~~dependences~~ dependencies, for the regulation of insulin secretion, food intake, memory functions, blood pressure, and of the electrolyte and energy balance and for the treatment of urinary incontinence or for the preparation of corresponding medicinal products.

3. (Currently Amended) Use The method according to claim 1 ~~or 2 of compounds comprising~~ administering an effective amount of a compound of the general formula



III

in which R' means alkyl, alkanoyl, alkenyl, alkynyl, alkoxycarbonylalkyl, alkoxycarbonylaminoalkanoyl, alkylcarbamoyl, alkoxycarbonylalkylcarbamoyl, alkoxycarbonylalkylthiocarbamoyl, alkylthiocarbamoyl, mono- or disubstituted aminoalkanoyl, aryl, arylalkyl, arylalkoxycarbonyl, arylalkanoyl, arylcarbamoyl, alkoxyalkanoyl, alkylsulphonyl, arylthiocarbamoyl, aryloxycarbonylalkyl, aryloxycarbonylalkanoyl, aryloxycarbonylalkylcarbamoyl, aryloxycarbonylalkylthio-carbamoyl, arylsulphonyl, cycloalkyl, cycloalkanoyl, cycloalkylcarbamoyl, cycloalkylthiocarbamoyl, cycloalkylcarbonyl, cycloalkyloxycarbonylalkyl, cycloalkyloxycarbonylalkanoyl, cycloalkyloxycarbonylalkylcarbamoyl, cycloalkyloxycarbonylalkyl-thiocarbamoyl, heteroarylalkyl, heterocyclalkyl, heterocyclalkoxycarbonylalkyl, heterocyclalkoxycarbonylalkanoyl, heterocyclalkoxycarbonylalkylcarbamoyl, heterocyclalkoxycarbonylalkylthiocarbamoyl, heteroaryloxycarbonylalkyl, heteroaryloxycarbonylalkylcarbamoyl or heteroaryloxycarbonylalkylthiocarbamoyl.

4. (Currently Amended) Use The method according to claim 3, in which the ring skeleton contains a thiazolopyridine, thiazoloazepine or thiazolooxepane skeleton, which ~~contains~~ includes only the two double bonds of the thiazole component.

5. (Currently Amended) Use The method according to claim 4, in which the ring skeleton is a 5,6-dihydro-4H-cyclopentathiazole, 6,7-dihydro-4H-pyrano[4,3-d]thiazole, or 5,6,7,8-tetrahydro-4H-thiazolo[4,5-c]azepine skeleton.

6. (Currently Amended) Use The method according to one of ~~claims 3-5~~ claim 3, in which R' ~~means~~ is methyl, ethyl, propyl, hexyl, 2,2-dimethylpropionyl, cyclopropylmethyl, 2-

cyclohexylethyl, propinyl, ethyloxycarbonylethyl, benzyl, n-butyloxycarbonyl, *tert*-butyloxycarbonyl, benzyloxy-carbonyl, 3-methyl-butyryl, pentanoyl, phenylacetyl, 2-propyl-pentanoyl, cyclopropanecarbonyl, isobutyryl, but-3-enoyl, 2-methoxy-acetyl, propane-2-sulphonyl, butane-1-sulphonyl, methanesulphonyl, *tert*-butyloxycarbonyl-aminopropionyl or 4-dimethylamino-butyryl.

7. (Currently Amended) Use The method according to claim ~~1 or 2~~ of 1, wherein said guanidine derivative is 2-guanidino-6,7-dihydro-4*H*-thiazolo[5,4-*c*]pyridine-5-carboxylic acid *tert*-butyl ester; N-(5-hexyl-4,5,6,7-tetrahydro-thiazolo[5,4-*c*]pyridine-2-yl)-guanidine; N-[5-(2-cyclohexyl-ethyl)-4,5,6,7-tetrahydro-thiazolo[5,4-*c*]pyridine-2-yl]-guanidine; N-(5-ethyl-4,5,6,7-tetrahydro-thiazolo[5,4-*c*]pyridine-2-yl)-guanidine; 2-guanidino-6,7-dihydro-4*H*-thiazolo[5,4-*c*]pyridine-5-carboxylic acid butyl ester; N-[5-(propane-2-sulphonyl)-4,5,6,7-tetrahydro-thiazolo[5,4-*c*]pyridine-2-yl]-guanidine; N-(5-phenylacetyl-4,5,6,7-tetrahydro-thiazolo[5,4-*c*]pyridine-2-yl)-guanidine; 2-guanidino-6,7-dihydro-4*H*-thiazolo[5,4-*c*]pyridine-5-carboxylic acid benzyl ester; N-(5-pentanoyl-4,5,6,7-tetrahydro-thiazolo[5,4-*c*]pyridine-2-yl)-guanidine; 2-guanidino-6,7-dihydro-4*H*-thiazolo[5,4-*c*]pyridine-5-thiocarboxylic acid propyl amide; N-[5-(2-propyl-pentanoyl)-4,5,6,7-tetrahydro-thiazolo[5,4-*c*]pyridine-2-yl]-guanidine; N-(5-benzyl-4,5,6,7-tetrahydro-thiazolo[5,4-*c*]pyridine-2-yl)-guanidine; N-(5-prop-2-ynyl-4,5,6,7-tetrahydro-thiazolo[5,4-*c*]pyridine-2-yl)-guanidine; N-(5-cyclopropanecarbonyl-4,5,6,7-tetrahydro-thiazolo[5,4-*c*]pyridine-2-yl)-guanidine; N-[5-(butane-1-sulphonyl)-4,5,6,7-tetrahydro-thiazolo[5,4-*c*]pyridine-2-yl]-guanidine; N-(5-isobutyryl-4,5,6,7-tetrahydro-thiazolo[5,4-*c*]pyridine-2-yl)-guanidine; N-[5-(2,2-dimethyl-propionyl)-4,5,6,7-tetrahydro-thiazolo[5,4-*c*]pyridine-2-yl]-guanidine; 2-guanidino-6,7-dihydro-4*H*-thiazolo[5,4-*c*]pyridine-5-thiocarboxylic acid benzyl amide; 2-guanidino-6,7-dihydro-4*H*-thiazolo[5,4-*c*]pyridine-5-carboxylic acid *tert*-butyl amide; N-(5-but-3-enoyl-4,5,6,7-tetrahydro-thiazolo[5,4-*c*]pyridine-2-yl)-guanidine; N-(5-benzyl-5,6,7,8-tetrahydro-4*H*-thiazolo[4,5-*c*]azepine-2-yl)-guanidine; 3-(2-guanidino-6,7-dihydro-4*H*-thiazolo[5,4-*c*]pyridine-5-yl)-propionic acid ethyl ester; 2-guanidino-6,7-dihydro-4*H*-thiazolo[5,4-*c*]pyridine-5-carboxylic acid pentyl amide; N-[5-(2-methoxy-acetyl)-4,5,6,7-tetrahydro-thiazolo[5,4-*c*]pyridine-2-yl]-guanidine; N-(5-cyclopropylmethyl-4,5,6,7-tetrahydro-thiazolo[5,4-*c*]pyridine-2-yl)-guanidine;

N-(5-methanesulphonyl-4,5,6,7-tetrahydro-thiazolo[5,4-c]pyridine-2-yl)-guanidine;  
 N-[5-(3-methyl-butyryl)-4,5,6,7-tetrahydro-thiazolo[5,4-c]pyridine-2-yl]-guanidine;  
 2-guanidino-6,7-dihydro-4*H*-thiazolo[5,4-c]pyridine-5-thiocarboxylic acid-(2-methoxy-1-methyl-ethyl)-amide; 2-guanidino-6,7-dihydro-4*H*-thiazolo[5,4-c]pyridine-5-carboxylic acid phenyl amide; [3-(2-guanidino-6,7-dihydro-4*H*-thiazolo[5,4-c]pyridine-5-yl)-3-oxo-propyl]-carbamic acid *tert*-butyl ester; N-[5-(4-dimethylamino-butyryl)-4,5,6,7-tetrahydro-thiazolo[5,4-c]pyridine-2-yl]-guanidine; N-(5-propyl-4,5,6,7-tetrahydro-thiazolo[5,4-c]pyridine-2-yl)-guanidine; ~~and~~ or 2-guanidino-6,7-dihydro-4*H*-thiazolo[5,4-c]pyridine-5-thiocarboxylic acid isopropyl amide.

8. (Currently Amended) ~~Compounds~~ A compound of Formula I ~~defined in claim 1~~, ; in which A ~~means~~ is a chain of 3-6 optionally substituted C atoms, one of which can be replaced by -O-, the ring skeleton containing only the two double bonds of the thiazole component; pharmaceutically applicable acid addition salts of basic compounds, pharmaceutically applicable salts of acid group-containing compounds with bases, pharmaceutically applicable esters of hydroxy or carboxy group-containing compounds as well as hydrates or solvates thereof; with the exception of

- N-(4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine;
- (2-guanidino-4,5,6,7-tetrahydro-benzothiazole-4-yl)-ethyl acetate ethyl ester;
- N-(4-hydroxymethyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine;
- N-(4-tosyloxymethyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine;
- N-(4-azidomethyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine;
- N-(4-aminomethyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine; and
- N-(6-acetylaminomethyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine.

9. (Currently Amended) ~~Compounds~~ The compounds according to claim 8, in which, in chain A

- one of the C atoms carries one or two identical or different substituents; or
- several of the C atoms each carry one or two identical or different substituents.

10. (Currently Amended) ~~Compounds~~ The compounds according to claim 9, in which the substituent(s) are ~~selected from~~ alkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, aralkyl,

alkoxycarbonyl, carboxamido, cyano or cyanolakyl groups and/or from polymethyl groups linked with one and the same C atom.

11. (Currently Amended) ~~Compounds~~ The compounds according to claim 10, in which the substituent(s) is/are ~~selected from~~

- methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, *sec*-butyl, *tert*-butyl, 1,1-dimethylpropyl, allyl and cyclohex-1-enyl groups; and/or
- phenyl, o-tolyl, m-tolyl, p-tolyl, 2-ethylphenyl, 3-fluorophenyl, 4-fluorophenyl, 4-chlorophenyl, 4-cyanophenyl, 4-benzyloxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl, 3,4-methylenedioxyphenyl and to-3,5-trifluoromethylphenyl groups; and/or
- thiophene-2-yl and benzyl groups; and/or
- ethoxycarbonyl groups; and/or
- n-propylamino, benzylamino, N-methyl-N-phenethylamino, 3-methylbutylamino, phenylamino, N-butyl-N-ethylamino, di-n-propylamino, allylamino, piperidine-1- and morpholine-4-carbonyl groups; and/or
- cyano and cyanoethyl groups; and/or
- pentamethylene groups linked with one and the same C atom.

12. (Currently Amended) ~~Compounds~~ The compounds according to claim 11, in which there is located on one and the same C atom on the one hand a phenyl group and on the other hand an ethoxycarbonyl, cyano or phenyl group.

13. (Currently Amended) *N*-(5-ethyl-5-methyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine and its formate; *N*-(5,5-dimethyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine and its formate; *N*-(5,5-dimethyl-6-phenyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine and its formate; *N*-(4-*tert*-butyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine; *N*-(6-isopropyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine; *N*-(5,5,7-trimethyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine; *N*-(6,6-dimethyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine; *N*-(5-butyl-5,6,7,8-tetrahydro-4*H*-cycloheptathiazol-2-yl)-guanidine;

*N*-(4-ethyl-4-methyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine;  
*N*-[6-(3,4-dimethoxyphenyl)-4,5,6,7-tetrahydro-benzothiazole-2-yl]-guanidine and its formate;  
*N*-(5-butyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine;  
*N*-(6-phenyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine;  
*N*-(5-methyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine;  
*N*-(4-methyl-4-propyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine;  
*N*-(6-propyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine;  
*N*-(4-cyclohex-1-enyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine and its formate;  
*N*-(4-*sec*-butyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine and its formate; ~~and~~ or  
*N*-(4-isobutyl-4-methyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine.

14. (Currently Amended) *N*-(6-*tert*-butyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine;  
 2-guanidino-6-phenyl-4,5,6,7-tetrahydro-benzothiazole-6-carboxylic acid ethyl ester and its  
 formate; *N*-[6-(1,1-dimethyl-propyl)-4,5,6,7-tetrahydro-benzothiazole-2-yl]-guanidine;  
*N*-(7-methyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine and its formate;  
*N*-[6-(3-methoxy-phenyl)-4,5,6,7-tetrahydro-benzothiazole-2-yl]-guanidine and its formate;  
*N*-(6-thiophene-2-yl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine and its formate;  
*N*-(5,5,7,7-tetramethyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine;  
*N*-[6-(4-fluorophenyl)-4,5,6,7-tetrahydro-benzothiazole-2-yl]-guanidine and its hydrobromide;  
 2-guanidino-4,5,6,7-tetrahydro-benzothiazole-6-carboxylic acid ethyl ester and its  
 hydrobromide; *N*-(4,4-dimethyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine;  
*N*-(4-methyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine and its formate;  
*N*-(4,5,6,7-tetrahydro-benzothiazole-2-yl-4-spiro-cyclohexane)-guanidine and its formate;  
*N*-(5,6,7,8-tetrahydro-4H-cycloheptathiazol-2-yl)-guanidine;  
*N*-(4-allyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine and its formate;  
*N*-(6-methyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine;  
*N*-[6-(3-fluorophenyl)-4,5,6,7-tetrahydro-benzothiazole-2-yl]-guanidine and its formate;  
*N*-(6-cyano-6-phenyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine and its hydrobromide;  
*N*-(4-phenyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine and its formate; ~~and~~ or  
*N*-(6,6-diphenyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine and its formate.

15. (Currently Amended) *N*-[6-(4-methoxy-phenyl)-4,5,6,7-tetrahydro-benzothiazole-2-yl]-guanidine and its hydrobromide; *N*-(5-phenyl-5,6,7,8-tetrahydro-4*H*-cycloheptathiazol-2-yl)-guanidine and its hydrobromide; *N*-(6,7-dihydro-4*H*-pyrano[4,3-*d*]thiazol-2-yl)-guanidine; *N*-(6-benzo[1,3]dioxol-5-yl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine and its formate; 2-guanidino-4,5,6,7-tetrahydro-benzothiazole-6-carboxylic acid propyl amide and its formate; *N*-[6-(4-cyanophenyl)-4,5,6,7-tetrahydro-benzothiazole-2-yl]-guanidine and its formate; *N*-(4-benzyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine and its formate; *N*-(5-methyl-5-phenyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine and its formate; *N*-[6-(3,5-to-trifluoromethylphenyl)-4,5,6,7-tetrahydro-benzothiazole-2-yl]-guanidine and its formate; *N*-(6-*o*-tolyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine and its formate; *N*-(6-*m*-tolyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine and its formate; *N*-[6-(2-ethyl-phenyl)-4,5,6,7-tetrahydro-benzothiazole-2-yl]-guanidine and its formate; *N*-[6-(4-chlorophenyl)-4,5,6,7-tetrahydro-benzothiazole-2-yl]-guanidine and its formate; 2-guanidino-4,5,6,7-tetrahydro-benzothiazole-4-carboxylic acid benzyl amide and its formate; *N*-(5,6-dihydro-4*H*-cyclopentathiazol-2-yl)-guanidine; *N*-[6-(4-benzyloxy-phenyl)-4,5,6,7-tetrahydro-benzothiazole-2-yl]-guanidine and its hydrobromide; 2-guanidino-4,5,6,7-tetrahydro-benzothiazole-4-carboxylic acid methyl phenethyl amide and its formate; *N*-(6-phenyl-4,5,6,7-tetrahydro-benzothiazole-2-yl-4-spiro-cyclohexane)-guanidine and its hydrobromide; *N*-(6-*p*-tolyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine and its formate 2-guanidino-4,5,6,7-tetrahydro-benzothiazole-4-carboxylic acid-(3-methyl-butyl)-amide and its formate; and or *N*-(4-*tert*-butyl-6-phenyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine.

16. (Currently Amended) 2-guanidino-4,5,6,7-tetrahydro-benzothiazole-6-carboxylic acid phenyl amide and its formate; 2-guanidino-4,5,6,7-tetrahydro-benzothiazole-4-carboxylic acid butyl ethyl amide and its formate; *N*-[4-(2-cyano-ethyl)-4,5,6,7-tetrahydro-benzothiazole-2-yl]-guanidine and its formate; 2-guanidino-4,5,6,7-tetrahydro-benzothiazole-4-carboxylic acid ethyl ester and its hydrobromide; 2-guanidino-4,5,6,7-tetrahydro-benzothiazole-4-carboxylic acid dipropyl amide and its formate; 2-guanidino-4,5,6,7-tetrahydro-benzothiazole-4-carboxylic acid phenyl amide and its formate; 2-guanidino-4,5,6,7-tetrahydro-benzothiazole-6-carboxylic acid allyl amide and its formate; 2-guanidino-4,5,6,7-tetrahydro-benzothiazole-4-carboxylic acid propyl amide and its formate; *N*-[4-(piperidine-1-carbonyl)-4,5,6,7-tetrahydro-benzothiazole-2-

yl]-guanidine and its formate; 2-guanidino-4,5,6,7-tetrahydro-benzothiazole-4-carboxylic acid allyl amide and its formate; 2-guanidino-4,5,6,7-tetrahydro-benzothiazole-6-carboxylic acid-(3-methyl-butyl)-amide and its formate; *N*-[4-(morpholine-4-carbonyl)-4,5,6,7-tetrahydro-benzothiazole-2-yl]-guanidine and its formate; ~~and~~ or 2-guanidino-4,5,6,7-tetrahydro-benzothiazole-4-carboxylic acid diisopropyl amide and its formate.

17. (Currently Amended) ~~Compounds~~ A therapeutic composition comprising the compound according to ~~one of claims 8-16 for use as therapeutic active ingredients~~ claim 8.

18. (Currently Amended) A medicinal product, ~~containing~~ comprising a compound according to ~~one of claims 8-16~~ claim 8 and an inert carrier.

19. (Currently Amended) ~~Use of compounds according to one of claims 8-16;~~ A method of antagonizing a neuropeptide FF receptor comprising administering to a patient an effective amount a compound according to claim ~~1 or 2~~ 8.


20. (Currently Amended) ~~Use of~~ A method of antagonizing a neuropeptide FF receptor comprising administering to a patient an effective amount of:

- N-(4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine;
- (2-guanidino-4,5,6,7-tetrahydro-benzothiazole-4-yl)-ethyl acetate ethyl ester;
- N-(4-hydroxymethyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine;
- N-(4-tosyloxymethyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine;
- N-(4-azidomethyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine;
- N-(4-aminomethyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine; and
- N-(6-acetylaminomethyl-4,5,6,7-tetrahydro-benzothiazole-2-yl)-guanidine

~~according to claim 1 or 2.~~

21. (Currently Amended) ~~Method~~ A method for the preparation of compounds according to ~~one of claims 8-16, characterized in that~~ claim 8, comprising halogenating a compound of the following Formula 1






is ~~halogenated~~ in  $\alpha$ -position to form the carbonyl group, subjecting the obtained compound of the above Formula 2 ~~is subjected~~ to a cyclocondensation with 2-imino-4-thiobiuret of the above Formula 3 and optionally converting an obtained basic compound ~~is converted~~ into a pharmaceutically applicable acid addition salt or an obtained compound, containing an acid group, into a pharmaceutically applicable salt with a base or an obtained, hydroxy- or carboxy group-containing, compound into a pharmaceutically applicable ester and optionally the obtained product into a hydrate or solvate.

**AMENDMENTS TO THE ABSTRACT:**

*Please add the following as the abstract:*



The invention relates to guanidine derivatives of formula (I) where: A represents a chain of 3-6 carbon atoms, one of which can be replaced by -N(R')- or -O- and R' is H or a substituent; the ring skeleton only contains both double bonds of the thiazole component; the pharmaceutically-acceptable acid addition salts of basic compounds of formula (I), the pharmaceutically-acceptable salts of compounds of formula (I), comprising acid groups, with bases, the pharmaceutically-acceptable esters of hydroxy or carboxyl group containing compounds of formula (I) and the solvates or hydrates thereof, which exhibit a neuropeptide FF receptor antagonist effect. The above are suitable for the treatment of pain and hyperalgesia, withdrawal symptoms in alcohol, psychotropic and nicotine dependencies, for improvement or cure of said dependencies, for regulation of insulin excretion, food intake, memory functions, blood pressure, electrolyte and energy management and for treatment of urinary incontinence. The above can be produced using generally used methods and processed to give medicaments.